Worldwide Insights on the Neurofibromatosis Type – 2 Industry to 2030 – Featuring AstraZeneca, Novartis and Pfizer Among Others –

March 29, 2021 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Neurofibromatosis Type – 2 – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to’s offering.

This report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Neurofibromatosis Type-2 (NF2) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

The Neurofibromatosis Type-2 market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Neurofibromatosis Type-2 market Size from 2017 to 2030, segmented by G-8 major markets. The report also covers the current Neurofibromatosis Type-2 treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Companies Mentioned

  • AstraZeneca
  • Novartis
  • Genentech
  • Takeda
  • Recursion Pharmaceuticals
  • Pfizer

Neurofibromatosis Type-2 Epidemiology

The Neurofibromatosis Type-2 epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every G-8 major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Neurofibromatosis Type-2 epidemiology segmented as the total diagnosed prevalent cases of Neurofibromatosis Type-2, age-specific cases of Neurofibromatosis Type-2, and tumor-specific cases of Neurofibromatosis Type-2. The report includes the prevalent scenario of Neurofibromatosis Type-2 symptoms in the G-8 covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030.

Country-wise Neurofibromatosis Type-2 Epidemiology

The epidemiology segment also provides the Neurofibromatosis Type-2 epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

The total diagnosed prevalence population of Neurofibromatosis Type-2 in the G-8 countries were 59,274 cases in 2020.

Neurofibromatosis Type-2 Drug Chapters

The drug chapter segment of the Neurofibromatosis Type-2 report encloses the detailed analysis of Neurofibromatosis Type-2 marketed drugs and late stage (Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the Neurofibromatosis Type-2 clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Currently, available treatments are non-curative. Despite the high morbidity associated with NF2 in severe cases, management of NF2-associated lesions primarily consists of surgical resection and treatment of symptoms.

Surgery can be used to remove most tumors, although it carries a risk of causing problems, such as complete deafness or facial weakness. Therefore, the risks and potential benefits need to be carefully considered before treatment. Small asymptomatic vestibular schwannomas can be managed conservatively with MRI follow-up. Surgery is the primary treatment for large symptomatic vestibular schwannomas. Also, localized radiation therapy is sometimes used for vestibular schwannomas, however, may risk the person’s hearing capacity as like surgery. Most people with NF2 eventually develop significant hearing loss and often benefit from using a hearing aid or learning to lip read. Special implants can sometimes be inserted to improve a person’s hearing. NF2 tends to get worse over time, although the speed at which this happens varies considerably.

Scope of the Report

  • The report covers the descriptive overview of Neurofibromatosis Type-2, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Neurofibromatosis Type-2 epidemiology and treatment in the G-8.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Neurofibromatosis Type-2 is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Neurofibromatosis Type-2 market; historical and forecasted, is included in the report, covering drug outreach in the G-8
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Neurofibromatosis Type-2 market

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Neurofibromatosis Type-2 market
  • To understand the future market competition in the Neurofibromatosis Type-2 market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Neurofibromatosis Type-2 in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Neurofibromatosis Type-2 market.
  • To understand the future market competition in the Neurofibromatosis Type-2 market.

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900